Yuta Adachi
Nagoya, 4648681, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
ARAF Amplification in Small-Cell Lung Cancer-Transformed Tumors Following Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors.
Journal: Cancers
Published: September 18, 2024
Inhibiting KRAS with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS and immune checkpoint inhibitor therapy.
Journal: Cell reports. Medicine
Published: May 27, 2024
SHP2 inhibitors maintain TGFβ signalling through SMURF2 inhibition.
Journal: NPJ precision oncology
Published: July 20, 2023
Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS.
Journal: Nature cancer
Published: July 29, 2022
Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers.
Journal: Cancers
Published: September 16, 2021
ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1.
Journal: Molecular cell
Published: April 18, 2021
Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 29, 2020
High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition.
Journal: Cell reports
Published: November 06, 2019
Aberrant Methylation of Tumor Suppressive miRNAs in Bile from Patients With Pancreaticobiliary Diseases.
Journal: Anticancer research
Published: July 22, 2019
Caput Medusae-like Venous Dilatation in Lung Cancer.
Journal: Internal medicine (Tokyo, Japan)
Published: July 12, 2019
Last Updated: 09/26/2026